Research programme: tumour metabolism and microenvironment modulators - Aravive Biologics

Drug Profile

Research programme: tumour metabolism and microenvironment modulators - Aravive Biologics

Alternative Names: 1-series; 3-series; 5-series; 7-series; M-series; STF-31

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Auckland Cancer Society Research Centre; Stanford University School of Medicine
  • Developer Aravive Biologics; Auckland Cancer Society Research Centre; Stanford University School of Medicine
  • Class Small molecules
  • Mechanism of Action Glucose transporter type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Ovarian cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in New Zealand
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top